No need for Celesio to rush into $5 bln deal
The value of patience
Folding the German drug distributor into American rival McKesson would yield big savings. But Celesio has no CEO, is only in talks with McKesson and its controlling family is struggling and wants cash. Courting more buyers may bump up the price and put minority investors at ease.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.